Updated Results of KEYNOTE 189
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health discusses the implications of the Alimta plus Keytruda based...
Author: obr
Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts
Update Of KEYNOTE-189 Trial: Evaluated The Addition Of Pembrolizumab To Platinum & Pemetrexed Chemotherapy In Patients With Metastatic Nonsquamous NSCLC
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses Update Of KEYNOTE-189 Trial: Evaluated The Addition Of Pembrolizumab To Platinum & Pemetrexed Chemotherapy In Patients With Metast...
Author: Annual-Meeting
Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and where these results fit into management of ...
Author: BeaconMedIC
Added: 12/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 2, 2018 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-189: chemo plus pembrolizumab for NSCLC
The KEYNOTE-189 ( NCT02578680) trial investigated the effects of adding pembrolizumab to cisplatin and pemetrexed in patients with non-small cell lung cancer (NSCLC). Here, Marina Garassino, MD, of th...
Author: VJOncology
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Thoughts on pemetrexed maintenance therapy
Mohammad Jahanzeb, MD, FACP, shares his thoughts on the continuation of pemetrexed maintenance after treatment of the patient with carboplatin, pemetrexed and pembrolizumab at ASCO 2018.
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Pemextrexed maintenance treatment
Roy S. Herbst, MD, PhD, shares his thoughts on whether to continue pemetrexed maintenance after successful treatment of the patient with carboplatin / pemetrexed / embrolizumab at ASCO 2018.
Author: obr
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Pemetrexed maintenance therapy
Edgardo S. Santos, MD, FACP, shares his opinion on continued pemetrexed maintenance at ASCO 2018
Author: obr
Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Continuation of pemetrexed maintenance
Joan Schiller, MD, shares her opinion on continuing pemetrexed maintenance after successful treatment with carboplatin, pemetrexed & pembrolizumab
Author: obr
Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy ...
Author: BeaconMedIC
Added: 07/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 9, 2018 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advance...
Author: BeaconMedIC
Added: 04/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2018 Category: Cancer & Oncology Source Type: podcasts
LUME-Meso Trial Pemetrexed, Cisplatin and Nintedanib Superior PFS
Anne S. Tsao, MD of MD Anderson Cancer Center discusses the LUME-Meso Trial using Pemetrexed, Cisplatin and Nintedanib demonstrates superior PFS from the 22nd Annual Perspectives in Thoracic Oncology ...
Author: thoraciconcology
Added: 12/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 29, 2017 Category: Cancer & Oncology Source Type: podcasts
INSPIRE Study - Dr. Parneet Cheema
For more updates visit www.oncologyeducation.com...
Video update from the 15th World Conference on Lung Cancer. Randomized phase 3- trial (INSPIRE) of Necitumumab plus cisplatin/pemetrexed versus cisp...
Author: oncologyeducation
Added: 11/05/2013 (Source: Oncology Tube)
Source: Oncology Tube - November 5, 2013 Category: Cancer & Oncology Source Type: podcasts
GRACEcast-109_Lung-Cancer_ASCO 2012 Lung Cancer Highlights: Dr. Mark Socinski on PARAMOUNT Trial
http://cancerGRACE.org/...
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in adva...
Author: cancergrace
Added: 01/17/2013 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2013 Category: Cancer & Oncology Source Type: podcasts
